Company Description
Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, Germany, the United Kingdom, and internationally.
It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.
The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile.
The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients’ homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors.
Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.
| Country | United States |
| Founded | 1901 |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 331,000 |
| CEO | Timothy Wentworth |
Contact Details
Address: 108 Wilmot Road Deerfield, Illinois 60015 United States | |
| Phone | 847 315 3700 |
| Website | walgreensbootsalliance.com |
Stock Details
| Ticker Symbol | WBA |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001618921 |
| CUSIP Number | 931427108 |
| ISIN Number | US9314271084 |
| Employer ID | 47-1758322 |
| SIC Code | 5912 |
Key Executives
| Name | Position |
|---|---|
| Stefano Pessina | Executive Chairman of the Board |
| Ramita Tandon | Chief Clinical Trials Officer |
| Joseph B. Amsbary Jr. | Senior Vice President and Corporate Secretary |
| Natasha Polster | Vice President of Pharmacy Quality, Compliance and Patient Safety |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Dec 13, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Dec 13, 2024 | ARS | Filing |
| Dec 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 13, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 2, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 10-K | Annual Report |